Like the hardiest weed, glioblastoma almost always springs backâusually within months after a patient's initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year ...
Aug 8, 2022
0
1770
Scientists at St. Jude Children's Research Hospital identified a molecular mechanism that in a preclinical study unlocked the promise of CAR T-cell therapy for treatment of solid tumors. The results were published today in ...
Jun 22, 2022
0
104
Researchers at Massachusetts General Hospital (MGH) have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell immunotherapy. ...
Jun 10, 2022
0
52
Before a patient can undergo T cell therapy designed to target cancerous tumors, the patient's entire immune system must be destroyed with chemotherapy or radiation. The toxic side effects are well known, including nausea, ...
Jun 8, 2022
0
89
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cells are more precise and sophisticated in their ability ...
Apr 15, 2022
0
27
Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal cancers (GICs) yet. ...
Mar 24, 2022
0
47
Results from the ZUMA-12 trial led by researchers at The University of Texas MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, ...
Mar 21, 2022
0
44
The first FDA-approved gene therapies are living drugs: immune cells taken from cancer patients engineered to target tumor cells. However, for many patients, these advanced therapies do not result in a long-lasting remission. ...
Mar 16, 2022
0
95
Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted ...
Feb 2, 2022
0
87
An experimental immunotherapy can temporarily reprogram patients' immune cells to attack a specific target via only a single injection of messenger RNA (mRNA), similar to the mRNA-based COVID-19 vaccines, according to a new ...
Jan 6, 2022
0
562
